Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Accured Expenses (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Change in Accured Expenses for 6 consecutive years, with -$615000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 91.57% to -$615000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.5 million, a 114.87% decrease, with the full-year FY2025 number at -$1.5 million, down 114.87% from a year prior.
  • Change in Accured Expenses was -$615000.0 for Q4 2025 at Relay Therapeutics, down from $3.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $17.9 million in Q3 2022 to a low of -$19.5 million in Q3 2023.
  • A 5-year average of $1.6 million and a median of $3.1 million in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: plummeted 303.8% in 2022, then soared 1159.06% in 2024.
  • Relay Therapeutics' Change in Accured Expenses stood at $7.9 million in 2021, then plummeted by 303.8% to -$16.1 million in 2022, then surged by 136.16% to $5.8 million in 2023, then plummeted by 224.94% to -$7.3 million in 2024, then soared by 91.57% to -$615000.0 in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Change in Accured Expenses are -$615000.0 (Q4 2025), $3.5 million (Q3 2025), and -$4.1 million (Q2 2025).